BioMed Research International / 2009 / Article / Tab 1

Research Article

Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer

Table 1

Patient’s characteristics entered into prospective study for high-risk patients ( ).

CharacteristicWPRT + N-ADT (group A)PORT (group B)

Patients ( )70 (100%)92 (100%)
Mean age (years)68.1 (range: 47–78)67.9 (range: 48–79).81
Gleason score
2–734 (49%)50 (55%).56
8–1036 (51%)42 (45%)
Clinical stage
T2c20 (29%)44 (48%).005
T350 (71%)48 (52%)
Total dose70.1 Gy70.3 Gy.22
PSA (ng/mL)
3025 (36%)41 (44%).32
3045 (64%)51 (56%)
% +
30%19 (27%)38 (41%).088
30%51 (73%)54 (59%)
Duration of L-ADT (months)28.429.1.13
Median followup (months)5455.21

WPRT: whole pelvic radiotherapy, PORT: prostate radiotherapy only, PSA: prostate specific antigen, N-ADT: neoadjuvant androgen deprivation therapy, L-ADT: long-term adjuvant androgen deprivation therapy, % +: probability of metastases to pelvic lymph nodes calculated according to the Roach formula [18].
*Unpaired -test for continuous variables; chi-square test for categorical variables.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.